Share Price

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q3FY26 results Revenue: Rs 580.39 crore against Rs 523.3 crore during Q3FY25, change 11%. PBT: Rs 27.55 crore against Rs 27.8 crore during Q3FY25, change -1%. PAT: Rs 20.58 crore against Rs 20.53 crore during Q3FY25, change 0%. EPS: Rs 0.7 for Q3FY26. Result PDF

• Trendlyne
• 4 months 1 week ago

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q2FY26 results Revenue from Operations: Rs 567.5 crore against Rs 525.8 crore during Q2FY25, change 7.9%. EBITDA: Rs 64.0 crore against Rs 48.0 crore during Q2FY25, change 33.3%. EBITDA Margin: 11.1% for Q2FY26. PAT: Rs 30.0 crore against Rs 19.2 crore during Q2FY25, change 56.7%. PAT Margin: 5.2% for Q2FY26. Vikas Gupta, Joint Managing Director, said: “Q2FY26 reflects IOL’s continued operational strength and strategic focus, with revenue from operations rising 7.9% and EBITDA improving 33.3% YoY. Importantly, EBITDA margin improved to 11.1% from 9.1%, driven by better operating leverage and cost efficiencies. Profit After Tax increased 56.7% YoY with PAT margin expanding to 5.2% from 3.6%, underscoring the strength of our integrated model. However, PAT was marginally impacted on a sequential basis due to higher fuel costs, following the Punjab floods, which temporarily disrupted supply chains and elevated energy inputs. Both our Pharmaceuticals and Chemicals segments reported YoY EBIT growth, reflecting improved operating discipline and recovery in volumes. The Pharmaceuticals segment continues to gain momentum, led by strong traction in non-Ibuprofen APIs. We also incorporated IOL Pharmaxis UK Limited, a strategic step to strengthen our international operations and improve customer proximity in key regions. In the Chemicals segment, we are witnessing steady volume recovery, even as pricing remains under pressure. Going ahead, our focus remains on cost optimisation, process discipline, and maintaining a balanced product mix across end-use sectors.” Result PDF

• Trendlyne
• 7 months 1 week ago

Pharmaceuticals company IOL Chemicals and Pharmaceuticals announced Q1FY26 results Revenue from Operations: Rs 551.7 crore compared to Rs 502.4 crore during Q1FY25, change 9.8%. EBITDA: Rs 69.5 crore compared to Rs 58.2 crore during Q1FY25, change 19.5%. EBITDA Margin: 12.4% for Q1FY26. PAT: Rs 34.0 crore compared to Rs 29.7 crore during Q1FY25, change 14.4%. PAT Margin: 6.1% for Q1FY26. Vikas Gupta, Joint Managing Director, said: “We are delighted to report an outstanding start to FY26, with Q1 results reflecting strong execution and strategic clarity. Despite challenging macroeconomic Conditions and pricing pressures, with several key product prices having bottomed out, IOL has delivered impressive performance, underscoring the resilience of our integrated business model. Our continued focus on portfolio diversification is yielding results, with non-Ibuprofen APIs gaining traction across global markets. With the commissioning of our fully backwardintegrated Paracetamol production unit, we are increasing our presence in both regulated and non-regulated markets. This positions us well to capture emerging opportunities, especially in regions where quality and compliance remain key differentiators. In the chemicals segment, the successful REACH registration of Acetic Anhydride under EU norms opens up new growth avenues in Europe, reinforcing our commitment to global standards and market expansion. As we move forward, our priorities remain clear — to scale high-value APIs, deepen our export footprint, and drive operational excellence. With a robust balance sheet and a strong innovation pipeline, we are confident in our ability to deliver sustainable growth and long-term value for all stakeholders.” Result PDF

• Trendlyne
• 10 months 2 weeks ago